LPH-48

Last updated

LPH-48
Clinical data
Other namesLPH48
Routes of
administration 		Unspecified [1]
Drug class Selective serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen [1] [2]

LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism. [1] [2] [3] Its route of administration has not been specified. [1]

Contents

The drug acts as a selective agonist of the serotonin 5-HT2A receptor. [1] [2] [3] It is said to be an analogue of LPH-5 with similar characteristics but with faster metabolism and a shorter duration of action. [3] LPH-5 is a highly selective serotonin 5-HT2A receptor agonist that is under development for major depressive disorder and has shown antidepressant-like effects in animals. [4] [5] [6]

LPH-48 is under development by Lophora. [1] [2] As of May 2024, it is in preclinical research for alcoholism. [1] [2] The chemical structure of LPH-48 does not yet seem to have been disclosed. [1] However, Lophora has patented selective serotonin 5-HT2A receptor agonists for treatment of depression [7] and the company is said to have patent protection for LPH-48. [1] Additionally, the structure of its close analogue LPH-5 is known and this compound is a phenylpiperidine derivative. [4]

See also

References

  1. 1 2 3 4 5 6 7 8 9 "LPH 48". AdisInsight. 22 May 2024. Retrieved 30 October 2024. LPH 48 is a ligand therapeutic which has a similar pharmacological profile as psilocybin with superior selectivity and shorter duration, being developed by [...]
  2. 1 2 3 4 5 "Delving into the Latest Updates on LPH-48 with Synapse". Synapse. 19 September 2024. Retrieved 30 October 2024.
  3. 1 2 3 Lophora (31 May 2024). "Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for Lead CNS Drug LPH-5" (PDF). Retrieved 30 October 2024. About LPH-48: LPH-48 is a shorter acting direct analog of LPH-5 with similar optimized characteristics and safety profile, but with a shorter duration of action. LPH-48 is designed as a fast-follower that shows significantly faster metabolism, indicating a shorter duration of action in man. LPH-48 is a representative of the same proprietary compound class as LPH-5 and is therefore endowed with the same optimized characteristics including favorable drug-like properties and a safe pharmacological profile.
  4. 1 2 M Ro Rsted E, Jensen AA, Smits G, Frydenvang K, Kristensen JL (May 2024). "Discovery and Structure-Activity Relationships of 2,5-Dimethoxyphenylpiperidines as Selective Serotonin 5-HT2A Receptor Agonists". Journal of Medicinal Chemistry. 67 (9): 7224–7244. doi:10.1021/acs.jmedchem.4c00082. PMC   11089506 . PMID   38648420.
  5. ↑ "LPH 5". AdisInsight. 7 March 2023. Retrieved 30 October 2024.
  6. ↑ Jensen AA, Cecchi CR, Hibicke M, Bach AH, Kaadt E, Marcher-Rorsted E, et al. (22 April 2024). "The selective 5-HT2Areceptor agonist LPH-5 induces persistent and robust antidepressant-like effects in rodents". bioRxiv. Cold Spring Harbor Laboratory. doi: 10.1101/2024.04.19.590212 .
  7. ↑ WO 2021/089824,Kristensen JL, Jensen AA, Märcher-Rørsted E, Leth-Petersen S,"5-HT2A agonists for use in treatment of depression",published 14 May 2021, assigned to Lophora ApS
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.